ClinicalTrials.gg
RecruitingNCT06879041Updated Oct 16, 2026

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 interventional study of AZD2287 and AZD2275 in Metastatic Castration-Resistant Prostate Cancer, sponsored by AstraZeneca. Recruiting at 16 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 16, 2026Site recruiting status changedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
136
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Planned enrollment
26th of 60
136 · median 110
Started
2025
with 9 others
Phase 1
13 of 91
1 open now
Primary completion
2029-04
later than 21 of 28 live
Registered
77th of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 26th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2025, is one of 13 in phase 1, reaches primary completion later than 21 of the 28 other live ones, and was the 77th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Read the detailed description

This is a first-in-human, Phase I, non-randomized, open-label clinical trial designed to evaluate AZD2284, AZD2287, and AZD2275.

This trial will consist of 2 Parts:

Part A (Imaging):

- Part A (Cold Antibody Exploration): aims to determine the optimal dosing regimen, with or without unconjugated antibody (AZD2275) pre-administration to improve the biodistribution of AZD2287.

Part B (Therapeutic):

  • Part B (Actinium-225 Dose Escalation): aims to assess the safety, tolerability, and efficacy of escalating doses of AZD2284 informed by the optimal dosing regimen identified in Part A.
  • Part B Expansion Cohorts 1 and 2: aims to explore efficacy of AZD2284.
03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • Dose Escalation Study
  • Metastatic Prostate Cancer
  • Radiopharmaceutical
  • Radiotheranostics
  • Castration-Resistant Prostate Cancer
  • Radiotherapy
  • Six Transmembrane Epithelial Antigen of the Prostate 2 (STEAP2)
  • Actinium
  • Radioconjugate
  • Radioligand
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • eria:
    • (ECOG) Performance Status of 0 or 1.
    • confirmed diagnosis of adenocarcinoma of the prostate without strong clinical suspicion of majority neuroendocrine differentiation.
    • Must have had prior bilateral orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum/plasma testosterone (\< 50 ng/dL or \< 1.7 nmol/L).
    • At least one lesion present on baseline Computed Tomography (CT), Magnetic Resonance Imaging (MRI), or bone scan obtained ≤ 28 days prior to the first dose of Medicinal Product (IMP). Participants may have non- including bone only metastases.
    • Adequate organ function
    • Part A only: Metastatic prostate cancer considered to be stable or progressing metastatic castration resistant prostate cancer (mCRPC).
    • Part B only: Progressing mCRPC defined as meeting at least one of following documented criteria -
  • a)Serum/plasma PSA progression
  • b)Soft-tissue progression
  • c)Progression of bone disease
    • Part B Dose Escalation: Previously treated with at least 2 prior lines of systemic anti-cancer therapy for mCRPC. Prior lines must include:
  • a)At least 1 androgen receptor pathway inhibitor (ARPI)
  • b)A poly (adp-ribose) polymerase (PARP) inhibitor for participants with known BRCA mutation
  • c)A for participants with known microsatellite instability-high (MSI-H), deficient mismatch pair (dMMR), or tumor mutational burden (TMB) ≥ 10 mut/Mb
    • Part B Dose Expansion: Previously treated with at least 1 prior line of systemic anti-cancer therapy for mCRPC. Prior lines must include:
  • (a)At least 1 ARPI
  • (b)A PARP inhibitor for participants with known BRCA mutation per local practice, unless ineligible per Investigator decision.
  • (c)A checkpoint inhibitor for participants with known MSI-H, dMMR, or TMB ≥ 10 mut/Mb.
  • (d)No previous cytotoxic chemotherapy for CRPC. Taxanes for metastatic hormone sensitive prostate cancer (mHSPC) is acceptable if the last cycle Day 1 was > 12 months before first study treatment.
  • (e)Previous treatment with prostate specific membrane antigen radioligand therapy (PSMA-RLT) or Radium-223 is allowed but not required. Participants who have had prior radiation therapy, including therapeutic radiopharmaceuticals, external bean radiation therapy (EBRT), and/or brachytherapy are eligible, subject to satisfying all other inclusion/exclusion criteria. Therapeutic radiopharmaceuticals will be considered a .
  • Main

Exclusion criteria

Exclusion Criteria:

    • Treatment with any radiopharmaceutical within 6 weeks of the first dose of Medicinal Product (IMP).
    • Radiation therapy (RT) or external beam radiation therapy (EBRT) within 28 days prior to the first dose and all RT-related events have not recovered to Grade ≤ 1.
    • Administration of any systemic cytotoxic or investigational therapy ≤ 28 days of the first dose of IMP or 5 half-lives, whichever is shorter.
    • All prior treatment-related adverse events must have resolved to Grade ≤ 1.
    • Concurrent severe and/or uncontrolled illness not related to cancer and/or social situation that would limit compliance with study requirements.
    • Known or suspected allergies or to any of the investigational drugs or any component of the investigational drug formulation.
    • proteinuria
    • Diffuse and intense osseous radiotracer uptake on bone scintigraphy or PSMA imaging characteristic of a superscan.
    • Chronic use greater than 10 mg prednisone equivalent daily.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    Part A: Cohort A1: AZD2287 (Hot only)

    Participants will receive AZD2287. If eligible for treatment, will receive dose level (DL)1 of AZD2284.

    Drug: AZD2287 · Drug: AZD2284

  • Experimental
    Part A: Cohort A2: AZD2275 + AZD2287 (Cold +Hot)

    Participants will receive DL1 of AZD2275 followed by AZD2287. If eligible for treatment, will receive DL1 of AZD2284.

    Drug: AZD2287 · Drug: AZD2275 · Drug: AZD2284

  • Experimental
    Part A: Cohort A3: AZD2275 + AZD2287 (Cold +Hot)

    Participants will receive DL2 of AZD2275 followed by AZD2287. If eligible for treatment, will receive DL1 of AZD2284.

    Drug: AZD2287 · Drug: AZD2275 · Drug: AZD2284

  • Experimental
    Part B (Actinium-225 Dose Escalation): DL1: AZD2284

    Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL1 of AZD2284.

    Drug: AZD2287 · Drug: AZD2275 · Drug: AZD2284

  • Experimental
    Part B (Actinium-225 Dose Escalation): DL2: AZD2284

    Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL2 of AZD2284.

    Drug: AZD2287 · Drug: AZD2275 · Drug: AZD2284

  • Experimental
    Part B (Actinium-225 Dose Escalation): DL3: AZD2284

    Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL3 of AZD2284.

    Drug: AZD2287 · Drug: AZD2275 · Drug: AZD2284

  • Experimental
    Part B (Actinium-225 Dose Escalation): DL4: AZD2284

    Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL4 of AZD2284.

    Drug: AZD2287 · Drug: AZD2275 · Drug: AZD2284

  • Experimental
    Part B: Cohort E1

    Participants will receive dose of AZD2284 determined by the earlier results. Expansion cohort may be opened to further characterize the safety and efficacy of the dose level.

    Drug: AZD2287 · Drug: AZD2275 · Drug: AZD2284

  • Experimental
    Part B: Cohort E2

    Participants will receive dose of AZD2284 determined by the earlier results. Expansion cohort may be opened to further characterize the safety and efficacy of the dose level.

    Drug: AZD2287 · Drug: AZD2275 · Drug: AZD2284

Interventions

  • DrugAZD2287

    Participants will receive AZD2287

  • DrugAZD2275

    Participants will receive AZD2275

  • DrugAZD2284

    Participants will receive AZD2284

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse event (AEs)

    Time frame: Part A: Up to Day 28; Part B: Up to 5 years

  2. Number of participants with Dose Limiting Toxicities (DLTs)

    Time frame: Part B: Up to 84 days of receiving AZD2284

  3. Estimates of residence time

    Time frame: Part A: Up to 8 days after a dose of AZD2287

  4. Absorbed radiation doses for AZD2287 and AZD2284

    Time frame: Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287

  5. Compare organ uptake of AZD2287 with and without pre-dose administration of AZD2275

    Time frame: Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287

  6. Tumor uptake of AZD2287 in selected regions of interest on SPECT/CT and/or planar images

    Time frame: Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287

Secondary outcomes

  1. Overall Response Rate (ORR)

    Time frame: Up to 12 months after the last dose of AZD2284

  2. Proportion of participants with Prostate-Specific Antigen (PSA) 50

    Time frame: Up to 12 months after the last dose of AZD2284

  3. Proportion of participants with PSA90

    Time frame: Up to 12 months after the last dose of AZD2284

  4. Time to PSA50 response

    Time frame: Up to 12 months after the last dose of AZD2284

  5. Duration of Response (DoR)

    Time frame: Up to 12 months after the last dose of AZD2284

  6. Radiographic Progression Free Survival (rPFS)

    Time frame: Up to 12 months after the last dose of AZD2284

  7. Overall Survival (OS)

    Time frame: Part A: Up to Day 28; Part B: Up to 5 years

  8. Pharmacokinetic Clearance

    Time frame: Part A: Up to Day 28; Part B: Up to 84 days

  9. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    Time frame: Part A: Up to Day 28; Part B: Up to 84 days

  10. Maximum observed drug concentration (Cmax)

    Time frame: Part A: Up to Day 28; Part B: Up to 84 days

  11. Half-life (t1/2)

    Time frame: Part A: Up to Day 28; Part B: Up to 84 days

  12. Changes in plasma concentrations of AZD2287 and AZD2284 following AZD2275 pre-administration compared to AZD2287 and AZD2284 alone

    Time frame: Part A: Up to Day 28; Part B: Up to 84 days

  13. Number of participants with positive antidrug antibodies (ADAs)

    Time frame: Part A: Up to Day 28; Part B: Approximately 28 days after End of Treatment (EOT) visit

07

Study locations

7 of 16 sites recruiting
  • Research Site
    Palo Alto, California 94304, United States
    Not yet recruiting
  • Research Site
    San Diego, California 92103, United States
    Not yet recruiting
  • Research Site
    Miami, Florida 33165, United States
    Recruiting
  • Research Site
    Tampa, Florida 33612, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60637, United States
    Recruiting
  • Research Site
    Metairie, Louisiana 70006, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Research Site
    Rochester, Minnesota 55902, United States
    Not yet recruiting
  • Research Site
    Omaha, Nebraska 68130, United States
    Recruiting
  • Research Site
    New York, New York 10032, United States
    Not yet recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • Research Site
    Portland, Oregon 97239, United States
    Not yet recruiting
  • Research Site
    East Melbourne, 3002, Australia
    Recruiting
  • Research Site
    CapeTown, 7925, South Africa
    Not yet recruiting
  • Research Site
    Durban, 4013, South Africa
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Pretoria, 181, South Africa
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicatesthat AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2029, 49 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 49 months is above that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Mar 17, 2025
StartActual
Mar 10, 2025
Primary completionEst.
Apr 16, 2029
CompletionEst.
Apr 16, 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Research Site is now Recruiting
Oct 16, 2026
Eligibility
12 inclusion criteria edited, 1 added; 1 criterion removed
What changed in the criteria
  • RemovedMain Exclusion Criteria:
Inclusion criteria
  • Addederia:
  • Editeda)Serum/plasma PSA progression
  • Editedb)Soft-tissue progression
  • Editedc)Progression of bone disease
  • Editeda)At least 1 androgen receptor pathway inhibitor (ARPI)
  • Editedb)A poly (adp-ribose) polymerase (PARP) inhibitor for participants with known BRCA mutation
  • Editedc)A checkpoint inhibitor for participants with known microsatellite instability-high (MSI-H), deficient mismatch pair (dMMR), or tumor mutational burden (TMB) ≥ 10 mut/Mb
  • Edited(a)At least 1 ARPI
  • Edited(b)A PARP inhibitor for participants with known BRCA mutation per local practice, unless ineligible per Investigator decision.
  • Edited(c)A checkpoint inhibitor for participants with known MSI-H, dMMR, or TMB ≥ 10 mut/Mb.
  • Edited(d)No previous cytotoxic chemotherapy for CRPC. Taxanes for metastatic hormone sensitive prostate cancer (mHSPC) is acceptable if the last cycle Day 1 was > 12 months before first study treatment.
  • Edited(e)Previous treatment with prostate specific membrane antigen radioligand therapy (PSMA-RLT) or Radium-223 is allowed but not required. Participants who have had prior radiation therapy, including therapeutic radiopharmaceuticals, external bean radiation therapy (EBRT), and/or brachytherapy are eligible, subject to satisfying all other inclusion/exclusion criteria. Therapeutic radiopharmaceuticals will be considered a prior line of systemic therapy.
  • EditedMain Inclusion Criteria:
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Research Site is now Recruiting
    Eligibility 12 inclusion criteria edited, 1 added; 1 criterion removed
    What changed in the criteria
    • RemovedMain Exclusion Criteria:
    Inclusion criteria
    • Addederia:
    • Editeda)Serum/plasma PSA progression
    • Editedb)Soft-tissue progression
    • Editedc)Progression of bone disease
    • Editeda)At least 1 androgen receptor pathway inhibitor (ARPI)
    • Editedb)A poly (adp-ribose) polymerase (PARP) inhibitor for participants with known BRCA mutation
    • Editedc)A checkpoint inhibitor for participants with known microsatellite instability-high (MSI-H), deficient mismatch pair (dMMR), or tumor mutational burden (TMB) ≥ 10 mut/Mb
    • Edited(a)At least 1 ARPI
    • Edited(b)A PARP inhibitor for participants with known BRCA mutation per local practice, unless ineligible per Investigator decision.
    • Edited(c)A checkpoint inhibitor for participants with known MSI-H, dMMR, or TMB ≥ 10 mut/Mb.
    • Edited(d)No previous cytotoxic chemotherapy for CRPC. Taxanes for metastatic hormone sensitive prostate cancer (mHSPC) is acceptable if the last cycle Day 1 was > 12 months before first study treatment.
    • Edited(e)Previous treatment with prostate specific membrane antigen radioligand therapy (PSMA-RLT) or Radium-223 is allowed but not required. Participants who have had prior radiation therapy, including therapeutic radiopharmaceuticals, external bean radiation therapy (EBRT), and/or brachytherapy are eligible, subject to satisfying all other inclusion/exclusion criteria. Therapeutic radiopharmaceuticals will be considered a prior line of systemic therapy.
    • EditedMain Inclusion Criteria:
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06879041
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Mar 10, 2025
Primary completion
Apr 16, 2029 (estimated)
Completion
Apr 16, 2029 (estimated)
Last update
Oct 16, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion